Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects
Abstract Parkinson’s disease is a neurodegenerative disorder involving the basal ganglia that results in a host of motor and cognitive deficits. Dopamine-replacement therapy ameliorates some of the hallmark motor symptoms of Parkinson’s disease, but whether these medications improve deficits in resp...
Guardado en:
Autores principales: | Peter Manza, Matthew Amandola, Vivekanand Tatineni, Chiang-shan R. Li, Hoi-Chung Leung |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4b5c41d63cb540489f4fd82cd18e3152 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Arm swing responsiveness to dopaminergic medication in Parkinson’s disease depends on task complexity
por: Elke Warmerdam, et al.
Publicado: (2021) -
Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?
por: MA Qamar, et al.
Publicado: (2017) -
Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease
por: Myung Jun Lee, et al.
Publicado: (2021) -
Astrocytes and retrograde degeneration of nigrostriatal dopaminergic neurons in Parkinson’s disease: removing axonal debris
por: Ingrid Morales, et al.
Publicado: (2021) -
Dopaminergic pathways and resting-state functional connectivity in Parkinson’s disease with freezing of gait
por: Kenan Steidel, et al.
Publicado: (2021)